Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

BACKGROUND: We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. METHODS: We calculated costs and quality-adjusted life-years from the UK National Hea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacoeconomics
Main Authors: Pennington, Becky, Alshreef, Abualbishr, Flight, Laura, Metry, Andrew, Poku, Edith, Hykin, Philip, Sivaprasad, Sobha, Prevost, A. Toby, Vasconcelos, Joana C., Murphy, Caroline, Kelly, Joanna, Yang, Yit, Lotery, Andrew, Williams, Michael, Brazier, John
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2021
Assuntos:
Original Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8298346/
https://ncbi.nlm.nih.gov/pubmed/33900585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-021-01026-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares